Login / Signup

Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab.

Anna SiemiątkowskaMaciej BrylKatarzyna Kosicka-NoworzyńJakub TvrdoňIwona Gołda-GockaFranciszek K Główka
Published in: Cancer immunology, immunotherapy : CII (2023)
Serum sCD8 could be an early biomarker of durable disease control after anti-PD-L1 treatment. Higher sCD8 in patients with worse outcomes could suggest the inhibitory effect of sCD8 on cytotoxic T-cells activation.
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • metabolic syndrome
  • type diabetes
  • combination therapy
  • skeletal muscle
  • smoking cessation
  • nk cells